# Daily Iterate Run Report — 2026-04-23

**Agent:** diabetes-research-iterate (automated scheduled task)
**Working dir:** `C:\Users\justi\OneDrive\Diabetes_Research`

## Work queue items processed

| Priority | Type | Target | Result |
|---|---|---|---|
| 1 | vet_papers_batch | 15 PMIDs (28397826, 28431241, 28522654, 28539434, 28776086, 28864502, 29291885, 29414425, 29562193, 29567707, 3899825, 8366922, 8439348, 9521319, 9742976) | 13 VETTED (5 tangential-noted), 2 FLAGGED |
| 2 | validate_path | NLRP3_inflammasome -> DKD | **VALIDATED** (HIGH preclinical/mechanistic; MEDIUM clinical) |
| 3 | audit_gap | Gap 14 (Personalized Nutrition for LADA, BRONZE) | Retained BRONZE |
| 3 | audit_gap | Gap 1 (Gene Therapy for LADA, SILVER) | Retained SILVER (first audit) |
| — | credibility_sweep | fabricated-PMID (>42M) + overstatement grep | Clean — 0 issues |
| — | rebuild_pipeline | run_quality_improvements.py | All 41 steps [OK] |

## Paper vetting detail

**Flagged (off-topic oncology, not diabetes):**
- PMID 28397826 — "Immune escape in the era of ICI" (Nat Rev Clin Oncol, 2017)
- PMID 29562193 — "Combination Cancer Therapy with Immune Checkpoint Blockade" (Immunity, 2018)

**Vetted with tangential notes (kept for background context):**
- PMID 28431241 — AKT/PKB signaling review (metabolic signaling background)
- PMID 28539434 — Estrogens in male physiology (sex-difference context for T2D)
- PMID 29291885 — SGA children growth outcomes (early-life programming)
- PMID 29567707 — CAR-T for cancer (background for CAR-Treg in T1D)
- PMID 9521319 — Dendritic cells (immunology background for T1D)

**Vetted on-topic (core corpus):**
- PMID 28522654 — Diabetic Kidney Disease: Challenges, Progress (Clin J Am Soc Nephrol)
- PMID 28776086 — Mechanisms of action of metformin (Diabetologia)
- PMID 28864502 — Sulfonylureas and AMI risk (Diabetes Care)
- PMID 29414425 — Neighborhood/food deserts/T2D (Health Place)
- PMID 3899825 — HOMA-IR/beta-cell original paper (Diabetologia 1985)
- PMID 8366922 — DCCT (N Engl J Med 1993)
- PMID 8439348 — IL-1 in disease (N Engl J Med 1993)
- PMID 9742976 — UKPDS-33 (Lancet 1998)

## NLRP3 -> DKD path validation — evidence

- **PMID 41357229 / PMC12675237** — Frontiers in Immunology 2025 systematic review: NLRP3 inflammasome in kidney disease, molecular mechanisms, small-molecule therapeutics
- **PMC12395217** — Mol Med Rep 2025 review: NLRP3 in diabetes and complications
- **PMC12206412** — NLRP3-mediated pyroptosis in DN: pathogenic mechanisms and therapeutic targets
- **ScienceDirect S1043466625001462** — PBMC-derived NLRP3 inflammasome mRNA signature tracks T2D-DKD progression (biomarker)
- **Olatec DAPAN-DIA** — First selective NLRP3 inhibitor (dapansutrile) Phase 2 RCT in T2D + diabetes-related complications (enrolled July 2024, N≈300, 6 months)
- **Ventyx VTX3232** — CNS-penetrant NLRP3 inhibitor Phase 2 for cardiometabolic risk
- Corpus already contained 61 data points on NLRP3 → inflammation and 3 on NLRP3 → nephropathy (PMIDs 39412512, 31036962)

**Status:** VALIDATED — mechanism very well supported; hard human clinical endpoints in DKD pending RCT readouts.

## Gap 14 audit (3rd pass, BRONZE → BRONZE)

No LADA-specific personalized-nutrition RCT found in April 2026 literature. The 2026 RSC Food & Function personalized-nutrition RCT review (d5fo02969d) and JMIR 2026 digital personalized-nutrition RCT (PMID 41490780) both exclude LADA. Adjacent pharmacotherapy beta-cell-preservation trials (Nature STTT 2023 saxagliptin+vitamin D; Hals 2019 early insulin; DPP-4i) continue but do not test a nutrition intervention. Gap retained BRONZE; opportunity remains wide open.

## Gap 1 audit (first pass, SILVER → SILVER)

Searches for "gene therapy LADA CRISPR 2026 beta cell clinical trial" confirm all active CRISPR/Cas diabetes cell-therapy programs (VCTX210A, VCTX211, CTX210A) remain T1D-focused. 2024 Biomolecules (PMID 37833064), 2024 AEMB (PMID 39824586), and 2023 IJMS "Trojan horse" (PMID 38139149) reviews omit LADA-specific gene-therapy work. The 2022 Front Endocrinol review (PMC9483094) of LADA β-cell protection argues the slower autoimmune process offers a longer therapeutic window but proposes immunomodulation/DPP-4i — not gene therapy. Retained SILVER.

## Credibility sweep

- Ripgrep across `Analysis/Scripts/*.py` for fabricated-PMID patterns (\\b4[2-9]\\d{6}\\b | \\b[5-9]\\d{7}\\b): **no matches**
- Grep for overstatement (zero SAE / zero rejection / curative / achieves): only known-milestone uses in `rebuild_research_dashboard.py` and model selectivity claims — no preclinical-as-cure violations

## Rebuild pipeline

`python Analysis/Scripts/run_quality_improvements.py` — **all 41 steps [OK]**.

## Running corpus totals

| Bucket | Count |
|---|---|
| VETTED | 140 |
| FLAGGED | 9 |
| UNVETTED | 118 |
| **Total papers** | **267** |

## Git commit status

**Commit blocked.** Stale lock files (`.git/index.lock`, `.git/HEAD.lock`) left by the 2026-04-22 run cannot be removed from the sandbox (OneDrive permission). All state and dashboard changes are saved to disk; a future interactive run (or an OS-level cleanup) can clear the locks and commit both 2026-04-22 and 2026-04-23 changes together. The `agent_state.json` run_history preserves full audit trail either way.

## Work queue after this run

1. [P1] vet_papers_batch — 118 unvetted papers remaining
2. [P2] search_pubmed — Abata ABA-201 CAR-Treg T1D readout
3. [P2] search_pubmed — DIAMYD GAD-alum DIAGNODE Extension follow-up
4. [P2] validate_path — SGLT2i → DKD (NLRP3 intermediate)  *(new, derived from today's path validation)*
5. [P3] audit_gap — Gap 7
6. [P3] search_pubmed — LADA-specific personalized nutrition RCT (monthly watch)
7. [P4] check_combination — dapagliflozin + colchicine + diabetes
8. [P4] search_pubmed — teplizumab long-term follow-up PROTECT extension
9. [P4] audit_gap — Gap 14 (next monthly, ~2026-05-23)
10. [P4] audit_gap — Gap 1 (next quarterly, ~2026-07-23)
